Ethical challenges in advanced heart failure

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 1, 2013, Pages 21-28

  Kini, Vinay ^a   Kirkpatrick, James N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Advance directives; Advanced heart failure; Ethics; Implantable cardioverter defibrillators; Ventricular assist devices

Indexed keywords

CAREGIVER; DECISION MAKING; ECONOMICS; ETHICS; HEALTH CARE DISPARITY; HEART ASSIST DEVICE; HEART FAILURE; HOSPICE CARE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFORMED CONSENT; LIVING WILL; PALLIATIVE THERAPY; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SOCIAL CLASS; STANDARD; STATISTICS;

ADVANCE DIRECTIVES; CAREGIVERS; DECISION MAKING; DEFIBRILLATORS, IMPLANTABLE; HEALTHCARE DISPARITIES; HEART FAILURE; HEART-ASSIST DEVICES; HOSPICE CARE; HUMANS; INFORMED CONSENT; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; SOCIAL CLASS;

EID: 84878000179     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32835c4915     Document Type: Review

References (63)

1. McMurray JJ, Petrie MC, Murdoch DR et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19 (Suppl. P): 9-16.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220.
3. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused Update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults. Circulation 2009;119:1977-2016.
4. Saunders C. The evolution of palliative care. J R Soc Med 2001;94:430-432.
5. World Health Organization. WHO definition of palliative care-2005. http://www.who.int/cancer/palliative/definition/en/print.html. [Accessed 7 2012].
6. Levy WC, Mozaffarian D, Linker DT. The Seattle Heart Failure Model - prediction of survival in heart failure. Circulation 2006;113:1424-1433.
7. Gorodeski EZ, Chu EC, Chow CH, et al. Application of the Seattle Heart Failure Model in ambulatory patients presented to an Advanced Heart Failure Therapeutics Committee. Circ Heart Fail 2010;3:706-714.
8. Gold Standards Framework. Prognostic indicator guidance: guidance to enable better identification of patients who may need supportive/palliative care. Revised version September 2008. www.goldstandardsframework. org.uk. [Accessed 7 2012].
9. Haga K, Murray S, Reid J, et al. Identifying community based chronic heart failure patients in the last year of life: a comparison of the Gold Standards Framework Prognostic Indicator Guide and the Seattle Heart Failure Model. Heart 2012;98:579-583.
10. Bekelman DB, Rumsfeld JS, Havranek EP, et al. Symptom burden, depression, and spiritual well-being: a comparison of heart failure and advanced cancer patients. J Gen Intern Med 2009;24:592-598.
11. Goebel JR, Doering LV, Shugarman LR, et al. Heart failure: the hidden problem of pain. J Pain Symptom Manage 2009;38:698-707.
12. Rose EA, Gelijns AC, Moskowitz AJ. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-1443.
13. Park SJ, Milano CA Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012;5:241-248.
14. Heffner JE, Barbieri C. End-of-life preferences of patients enrolled in cardiovascular rehabilitation programs. Chest 2000;117:1474-1481.
15. Kirkpatrick JN, Guger CJ, Arnsdorf MF, Fedson SE. Advance directives in the cardiac care unit. Am Heart J 2007;154:477-481.
16. Janssen DJ, Spruit MA, Schols JM, Wouters EF. A call for high-quality advance care planning in outpatients with severe COPD or chronic heart failure. Chest 2011;139:1081-1088. This important study followed a cohort of patients with NYHA Class III or IV heart failure and assessed their life-sustaining treatment preferences, advance care planning, and quality of end-of-life care communication with their specialist physician. While patients' burden of treatment and outcome of treatment affected their end-of-life care preferences, their physicians rarely discussed prognosis, dying, and palliative care. This study demonstrates the need for specialist physician involvement in advance care planning.
17. Habal MV, Micevski V, Greenwood S, et al. How aware of advance care directives are heart failure patients, and are they using them? Can J Cardiol 2011;27:376-381. This study showed that a vast majority of patients with heart failure had never discussed an advance directive with their cardiologist, but most would have preferred to. This study suggests that care providers should devote time during a patient's visit to discuss advance directives.
18. Bain KT, Maxwell TL, Strassels SA, Whellan DJ. Hospice use among patients with heart failure. Am Heart J 2009;158:118-125.
19. Wingate S, Bain KT, Goodlin SJ. Availability of data when heart failure patients are admitted to hospice. Congest Heart Fail 2011;17:303-308. This important study showed that for patients with heart failure, transition of care to hospice is poor. Clinically relevant data such as presence of symptoms, ejection fraction, and presence of a pacemaker were not provided to or obtained by the hospice providers in a significant amount of the time.
20. Goldstein N, Carlson M, Livote E, Kutner JS. Management of implantable defibrillators in hospice. Ann Intern Med 2010;152:296-299.
21. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-1940.
22. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341: 1882-1890.
23. Leosdottir M, Sigurdsson E, Reimarsdottir G, et al. Health-related quality of life of patients with implantable cardioverter defibrillators compared with that of pacemaker recipients. Europace 2006;8:168-174.
24. Cho EN, von Kanel R, Marten-Mittag B, et al. Determinants and trajectory of phobic anxiety in patients living with an implantable cardioverter defibrillator. Heart 2012;98:806-812. This study showed that patients with ICDs have levels of phobic anxiety that are quite high and persist over time. They also identified risk factors such as greater age, previous shocks, and depression which may be used to screen patients for early intervention such as counseling and support groups.
25. Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res 2011;71:223-231.
26. Morgan K. Death and defibrillators: implanted devices keep shocking as heartbeat changes near life's end. The Charleston Gazette 26 June 2006, 1D.
27. Goldstein NE, Lampert R, Bradley E, et al. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med 2004;141: 835-838.
28. Tajouri TH, Ottenberg AL, Hayes DL, Mueller PS. The use of advance directives among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2012;35:567-573. This study showed that only a small number of patients who undergo ICD implantation for primary prevention has an advance directive. An even smaller number (2 of 420) had an advance directive that specifically mentioned the ICD. This study highlights the lack of advance care planning in the management of ICDs.
29. Kirkpatrick JN, Gottlieb M, Sehgal P, et al. Deactivation of implantable cardioverter defibrillators in terminal illness and end of life care. Am J Cardiol 2012;109:91-94. This study showed that patients with ICDs have a poor understanding of ICD deactivation and varying attitudes towards deactivation in an end-of-life situation. Although very few patients had an advance directive that mentioned the ICD, most patients wished to discuss ICD deactivation with their care provider.
30. Raphael CE, Koa-Wing M, Stain N, et al. Implantable cardioverter- defibrillator recipient attitudes towards device deactivation: how much do patients want to know? Pacing Clin Electrophysiol 2011;34:1628-1633. This important study showed that most patients who had an ICD placed for primary prevention did not know that an ICD could be deactivated. As many patients felt that a discussion on ICD deactivation should occur prior to implantation, care providers should include advance care planning as part of the discussion prior to ICD implantation.
31. Mezu U, Adelstein E, Jain S, Saba S. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death. Am J Cardiol 2011;108:718-722. This study examined the effectiveness of ICDs in prolonging life in patients older than 80 years of age, and found that after adjusting for comorbidities such as glomerular filtration rate and age, ICDs did not appear to confer a survival benefit. This study is important in that the findings suggest a possibility of using age and GFR cutoffs as indications for ICD deactivation.
32. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. JAMA 2003;289:2685-2694.
33. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
34. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS annual report: the evolution of destination therapy in the United States . J Heart Lung Transplant 2011;30:115-123.
35. Swetz KM, Freeman MR, AbouEzzeddine OF, et al. Palliative medicine consultation for preparedness planning in patients receiving left ventricular assist devices as destination therapy. Mayo Clin Proc 2011;86:493-500. The authors of this study describe their experience providing palliative care consultation for patients planning to undergo LVAD implantation as destination therapy. They focused on preparedness planning, completion of advance directives, and periodic reassessment of quality of life and goals of care.
36. Petrucci RJ, Benish LA, Carrow BL, et al. Ethical considerations for ventricular assist device support: a 10-point model. ASAIO J 2011;57:268-273. This important study provides a model to address the ethical and psychosocial issues that should be discussed with patients undergoing VAD support. They include the risks and benefits of device placement, an advance directive, and plans for device replacement or withdrawal.
37. Mueller PS, Swetz KM, Freeman MR, et al. Ethical analysis of withdrawing ventricular assist device support. Mayo Clin Proc 2010;85:791-797.
38. Brush S, Budge D, Alharethi R, et al. End-of-life decision making and implementation in recipients of a destination left ventricular assist device. J Heart Lung Transplant 2010;29:1337-1341.
39. Bramstedt KA. Left ventricular assist devices and the slippery slope of ageism. Int J Cardiol 2001;81:201-203.
40. Sindone AP, Keogh AM, Macdonald PS, et al. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 1997;134:889-900.
41. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990;18:530-533.
42. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery hemodynamic monitoring in heart failure: a randomized controlled trial. Lancet 2011;377:658-666.
43. US Department of Health and Human Services. National Healthcare Disparities Report 2011. AHRQ Publication No. 12-0006. March 2012. www.ahrq.gov/qual/qrdr11.htm.
44. Rogers JG, Bostic RR, Tong KB, et al. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 2012;5:10-16. This study calculates the incremental cost-effectiveness of continuous flow LVADs at approximately US$200 000. Although still not costeffective under currently accepted guidelines, this represents a significant improvement over the original pulsatile flow device.
45. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischemic or nonischemic heart disease: an European analysis. Eur Heart J 2012 Advance Access. doi: 10.1093/eurheartj/ehs090. Available online at http:/eurheartj. oxfordjournals.org. This study calculates the incremental cost-effectiveness of primary prophylaxis implantable cardioverter defibrillators for cardiomyopathy at less than 50 000 euros. This suggests that ICDs are costeffective in the European setting.
46. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-1480.
47. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004;141:343-351.
48. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverterdefibrillator. Eur Heart J 2007;28:42-51.
49. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. Circulation 2008;117:2820-2840.
50. Imes CC, Dougherty CM, Pyper G, et al. Descriptive study of partners' experiences of living with severe heart failure. Heart Lung 2011;40:208-216. The authors of this study conducted interviews with caregivers of patients with heart failure, and found that caregiving results in social isolation and difficulties in planning for the future.
51. Hwang B, Fleischmann KE, Howie-Esquivel J, et al. Caregiving for patients with heart failure: impact on patients' families. Am J Crit Care 2011;20:431-442.
52. Trivedi RB, Piette J, Fihn SD et al. Examining the interrelatedness of patient and spousal stress in heart failure: conceptual model and pilot data. J Cardiovasc Nurs 2012;27:24-32. The authors of this study conducted interviews with patients with heart failure and their spouses, and found high levels of depression and caregiver burden.
53. Hawkins NM Jhund PS, McMurray JJ, et al. Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail 2012;14:138-146. The authors of this study conducted an international meta-analysis of 28 studies that examined the impact of socioeconomic status on heart failure, and found that patients with lower socioeconomic status have an increased prevalence of heart failure and higher mortality from heart failure.
54. Chaudhry SI, Herrin J, Phillips C, et al. Racial disparities in health literacy and access to care among patients with heart failure. J Card Fail 2011;17:122-127. The authors of this study showed that among patients with heart failure, black race was strongly associated with worse health literacy and all measures of poor access to care.
55. Vaccarino V, Parsons L, Peterson ED, et al. Sex differences in mortality after acute myocardial infarction: changes from. Arch Intern Med 2009;169:1767-1774.
56. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
57. Tendera M. Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe . Eur Heart J Suppl 2005;7:J5-J9.
58. Setoguchi S, Glynn RJ, Stedman M, et al. Hospice, opiates, and acute care service use among the elderly before death from heart failure or cancer. Am Heart J 2010;160:139-144.
59. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012;125:1928-1952.
60. Lampert R, Hayes DL, Annas GJ, et al. HRS expert consensus statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010;7:1008-1026.
61. McKelvie RS, Moe GW, Cheung A, et al. The 2011 Canadian Cardiovascular Society heart failure guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011;27:319-338.
62. Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Europace 2008;10:707-725.
63. Goodlin SJ, Hauptman PJ, Arnold R, et al. Consensus statement: palliative and supportive care in heart failure. J Card Fail 2004;10:200-209.